Rapid amelioration of anorexia nervosa in a male adolescent during metreleptin treatment including recovery from hypogonadotropic hypogonadism

被引:36
|
作者
Antel, Jochen [1 ,4 ,5 ]
Tan, Susanne [2 ]
Grabler, Marvin [1 ]
Ludwig, Christine [1 ]
Lohkemper, Dominik [1 ]
Brandenburg, Tim [2 ]
Barth, Nikolaus [1 ]
Hinney, Anke [1 ]
Libuda, Lars [1 ]
Remy, Miriam [1 ]
Milos, Gabriella [3 ]
Hebebrand, Johannes [1 ]
机构
[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Child & Adolescent Psychiat, Essen, Germany
[2] Univ Duisburg Essen, Univ Hosp Essen, Dept Endocrinol Diabet & Metab, Essen, Germany
[3] Univ Zurich, Univ Hosp Zurich, Dept Consultat Liaison Psychiat & Psychosomat Med, Eating Disorders Unit, Zurich, Switzerland
[4] Univ Duisburg Essen, Univ Hosp Essen, Dept Child & Adolescent Psychiat, Res Unit,Psychosomat & Psychotherapy,LVR Klinikum, Virchowstr 174, D-45147 Essen, Germany
[5] KJP Forsch Abt, Holsterhauser Pl 2,Cranachhofe 2,Raum 32, D-45147 Essen, Germany
关键词
Anorexia nervosa; Metreleptin; Antidepressive; Hypogonadotropic hypogonadism; Hyperactivity; SERUM LEPTIN; GONADOTROPIN; DEPRESSION; BRAIN; WOMEN;
D O I
10.1007/s00787-021-01778-7
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
With this case report we support our medical hypothesis that metreleptin treatment ameliorates starvation related emotional, cognitive and behavioral symptomatology of anorexia nervosa (AN) and show for the first time strong effects in a male patient with AN. A 15.9 year old adolescent with severe AN of eight-month duration was treated off-label with metreleptin. Hyperactivity was assessed with accelerometry. Visual analogue scales (VAS), validated self- and clinician rating scales and lab results tracked changes from baseline to end of the 24-day dosing period and a five-month follow-up. Substantial improvements of mood and eating disorder related cognitions and hyperactivity set in after two days of treatment. During dosing, sub-physiological testosterone and TT3 levels normalized; clinically libido reemerged. Weight did not increase substantially during the dosing period. During follow-up target weight was attained; mood did not deteriorate; hyperactivity ceased. The results substantiate the strong effects seen in female cases and underscore the need for a double-blind placebo-controlled trial to confirm the observed strong, multiple and rapid onset beneficial effects of metreleptin in AN.
引用
收藏
页码:1573 / 1579
页数:7
相关论文
共 40 条
  • [21] Qualitative study of the impact on recovery of peer relationships between female inpatients during treatment for anorexia nervosa in the United Kingdom
    Lotery, Elizabeth
    Bell, Rebecca
    Combe, Gillian
    Biddle, Lucy
    Bould, Helen
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2024, 57 (02) : 353 - 362
  • [22] Involuntary Treatment for Child and Adolescent Anorexia Nervosa-A Narrative Review and Possible Advances to Move Away from Coercion
    Zielinski-Gussen, Ingar M.
    Herpertz-Dahlmann, Beate
    Dahmen, Brigitte
    HEALTHCARE, 2023, 11 (24)
  • [23] Experiences of patients with anorexia nervosa during the transition from child and adolescent mental health services to adult mental health services
    Veronica Lockertsen
    Liv Nilsen
    Lill Ann Wellhaven Holm
    Øyvind Rø
    Linn May Burger
    Jan Ivar Røssberg
    Journal of Eating Disorders, 8
  • [24] Experiences of patients with anorexia nervosa during the transition from child and adolescent mental health services to adult mental health services
    Lockertsen, Veronica
    Nilsen, Liv
    Holm, Lill Ann Wellhaven
    Ro, Oyvind
    Burger, Linn May
    Rossberg, Jan Ivar
    JOURNAL OF EATING DISORDERS, 2020, 8 (01)
  • [25] Risk factors for a low weight gain in the early stage of adolescent anorexia nervosa inpatient treatment: findings from a pilot study
    Nadja Knoll-Pientka
    Judith Bühlmeier
    Triinu Peters
    Muriel Albrecht
    Frederike Adams
    Katharina Wustrau
    Martin Teufel
    Johannes Hebebrand
    Manuel Föcker
    Lars Libuda
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2020, 25 : 911 - 919
  • [26] Risk factors for a low weight gain in the early stage of adolescent anorexia nervosa inpatient treatment: findings from a pilot study
    Knoll-Pientka, Nadja
    Buehlmeier, Judith
    Peters, Triinu
    Albrecht, Muriel
    Adams, Frederike
    Wustrau, Katharina
    Teufel, Martin
    Hebebrand, Johannes
    Foecker, Manuel
    Libuda, Lars
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2020, 25 (04) : 911 - 919
  • [27] MALE ANOREXIA AND BULIMIA NERVOSA: DISORDER SYMPTOMS AND IMPULSIVE BEHAVIOUR DURING HOSPITAL TREATMENT AND ONE YEAR FOLLOW-UP PERIOD
    Sernec, Karin
    Mrevlje, Gorazd V.
    Carapic, Jadranka
    Weber, Urska
    Zalar, Bojan
    PSYCHIATRIA DANUBINA, 2015, 27 (03) : 242 - 249
  • [28] Physical restraint during inpatient treatment of adolescent anorexia nervosa: frequency, clinical correlates, and associations with outcome at five-year follow-up
    Blikshavn, Thomas
    Halvorsen, Inger
    Ro, Oyvind
    JOURNAL OF EATING DISORDERS, 2020, 8 (01)
  • [29] Vitamin D Level Trajectories of Adolescent Patients with Anorexia Nervosa at Inpatient Admission, during Treatment, and at One Year Follow Up: Association with Depressive Symptoms
    Foecker, Manuel
    Timmesfeld, Nina
    Buehlmeier, Judith
    Zwanziger, Denise
    Fuehrer, Dagmar
    Grasemann, Corinna
    Ehrlich, Stefan
    Egberts, Karin
    Fleischhaker, Christian
    Wewetzer, Christoph
    Wessing, Ida
    Seitz, Jochen
    Herpertz-Dahlmann, Beate
    Hebebrand, Johannes
    Libuda, Lars
    NUTRIENTS, 2021, 13 (07)
  • [30] Multidisciplinary implementation of family-based treatment delivered by videoconferencing (FBT-V) for adolescent anorexia nervosa during the COVID-19 pandemic
    Couturier, Jennifer
    Pellegrini, Danielle
    Grennan, Laura
    Nicula, Maria
    Miller, Catherine
    Agar, Paul
    Webb, Cheryl
    Anderson, Kristen
    Barwick, Melanie
    Dimitropoulos, Gina
    Findlay, Sheri
    Kimber, Melissa
    McVey, Gail
    Lock, James
    TRANSLATIONAL BEHAVIORAL MEDICINE, 2023, 13 (02) : 85 - 97